Navigation Links
Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
Date:10/5/2010

c reports on Form 10- Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Oct. 5, 2010 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... NxStage Medical, Inc. (NASDAQ: NXTM ... announced today that the U.S. Food and Drug ... perform hemodialysis overnight while the patient is at ... System One is the first and only hemodialysis ... Home nocturnal hemodialysis is an ...
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today issued the following open letter to ... , Dr. Med. Sc. Dear RXi ... a number of inaccurate statements posted on certain ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... Dec. 3, 2010 Streamline Health Solutions, Inc. (Nasdaq: ... quarter fiscal year 2010 financial results for the period ended ... market closes. The Company will conduct a conference call and ... 2010 at 4:30 p.m. ET. Interested parties can ...
... 3, 2010 InfraReDx, Inc. , a medical ... announced that James E. Muller, M.D., founder and chief ... Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference, to be ... San Francisco. The InfraReDx presentation is ...
Cached Medicine Technology:Streamline Health to Announce Third Quarter Fiscal Year 2010 Financial Results on Wednesday, December 8 2
(Date:12/26/2014)... (PRWEB) December 26, 2014 Parker ... for the best in heating, cooling and plumbing ... 24 hour emergency services in 2014 with regard ... know that Arizona is known for its incredibly ... that understands the intricacies and details of a ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
(Date:12/25/2014)... December 26, 2014 Recently, iFitDress.com, the popular ... women, has announced its new selection of black one-shoulder ... on sale now; they are available at discounted prices, up ... “The promotion will last for three weeks only. You know, ... Those who are interested in our new items can visit ...
(Date:12/25/2014)... 2014 BambooFlooringChina.com sells many bamboo products ... flooring. Today, the company announces big discounts on ... and colors. , BambooFlooringChina.com is the world’s leader in ... is valid until Jan. 20, 2015. , The bamboo ... with a natural thread. All the bamboo strips for ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... sick children with complex chronic illnesses can receive effective, less ... home," with easy access to a team of dedicated health ... likely to become seriously ill and need either hospitalization or ... at an enhanced medical home clinic at the University of ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... Offices of Howard G. Smith,announces a December 3, 2007, ... securities class action lawsuit filed on behalf of shareholders ... or,the "Company")(Nasdaq: MEND ) between February 12, 2007 ... lawsuit is pending in,the United States District Court for ...
... FRANCISCO, Calif., Nov. 8 Monogram,Biosciences, Inc. (Nasdaq: ... CEO, is scheduled to present a corporate overview at ... 2007,at 8:00 a.m. (Eastern Time) at the New York ... or the subsequent archived,recording, log on to http://www.monogrambio.com ...
... risk factor for injury, study finds , THURSDAY, Nov. ... to their medications may cut their risk for fracture, ... a fracture, there,s an increased risk of additional fractures, ... of fractures in osteoporosis patients are hip, spine, and ...
... an overwhelming majority, 90 percent of Americans, claim a ... more religiously diverse than ever before, which is why ... where clients beliefs stem from, says Dr. E. Thomas ... are much less religious than the general population, says ...
... molecular switch in the protein making machinery of cells is ... breast cancer worldwide. The discovery by researchers at NYU School ... called locally advanced breast cancer (LABC)., ... 50 percent or more of breast cancers among women in ...
... Transfer Challenge Awards all have a strong track record in ... , This competition is also about coming up with new ... that research is transformed into products and services that everyone ... record in Knowledge Transfer: , Aston University ...
Cached Medicine News:Health News:Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference 2Health News:Sticking With Meds Lowers Elderly Fracture Risk 2Health News:A molecular switch is linked to a common breast cancer 2Health News:Final of EPSRC's 2007 Knowledge Transfer Challenge Awards 2
... Anatomically Correct Design Is Unique Among All Lid ... Support The Lids Through An Anatomically Correct Arc ... With All Other Lid Speculums Which Pull Straight ... Tarsal Plate As They Open. Gentle Support ...
... Footplates Are Turned 90 Degrees To ... Blade While Incising Tissue. ,Special Mirror-Polished Double ... Penetration.,Pre-Set Blade Extension Settings Of 0.5mm, ... Full Extension.,1mm Wide Snub Nose Diamond ...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Pocket-sized instrument with 2.5X magnification....
Medicine Products: